MeritValue

Yubo International Biotech Ltd

YBGJdata completeness 75%17 fiscal years on file

Data notes: no data for concept 'totalDebt'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1.24M1$104,2832$604,6763$3,4704$12,3534
Net income−$1.54M5−$1.2M6−$1.2M7−$1.78M8−$1.08M8
Operating cash flow−$1.02M9−$600,95310−$738,97111−$1.34M12−$842,80212
Capital expenditure$564,71813$013———
Free cash flow (derived)−$1.59M9−$600,95310———
Total debt—————
Cash & equivalents$27,51714$18,22015$6,35916$7,01517$8,06218
Diluted shares——12.0M119.8M139.6M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.14
your share of equity
Profit it earned you last year
−$0.08
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$0.14 of net worth that earned you −$0.08 last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+1065% shares · 5y

Share count is up 1065% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001640334-23-000632 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001640334-24-000618 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001640334-25-000547 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001640334-26-000598 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001640334-23-000632 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001640334-24-000618 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001640334-25-000547 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001640334-26-000598 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001640334-23-000632 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001640334-24-000618 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001640334-25-000547 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001640334-26-000598 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2021-12-31 · accession 0001640334-23-000632 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2021-12-31 · accession 0001640334-22-000807 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2022-12-31 · accession 0001640334-23-000632 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K · period ending 2023-12-31 · accession 0001640334-24-000618 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2024-12-31 · accession 0001640334-25-000547 (CashAndCashEquivalentsAtCarryingValue)
  18. 10-K · period ending 2025-12-31 · accession 0001640334-26-000598 (CashAndCashEquivalentsAtCarryingValue)